Ariad Reaches New 52-Week High (ARIA)
NEW YORK (
) --
(Nasdaq:
) hit a new 52-week high Friday as it is currently trading at $15.47, above its previous 52-week high of $15.44 with 2.6 million shares traded as of 2:50 p.m. ET. Average volume has been 3.2 million shares over the past 30 days.
Ariad has a market cap of $2.29 billion and is part of the
sector and
industry. Shares are up 22.9% year to date as of the close of trading on Thursday.
ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Ariad as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full
.
See all
52-week high stocks
or get investment ideas from our
.
null
